Relevant bibliographies by topics / Anti-cancer drugs / Journal articles

Journal articles on the topic 'Anti-cancer drugs'

To see the other types of publications on this topic, follow the link: Anti-cancer drugs.
Author: Grafiati
Published: 4 June 2021
Last updated: 9 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anti-cancer drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tahara, Makoto. "Anti-cancer drugs for thyroid cancer." Annals of Oncology 28 (October 2017): ix63. http://dx.doi.org/10.1093/annonc/mdx612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kabir, Md Lutful, Feng Wang, and Andrew H. A. Clayton. "Intrinsically Fluorescent Anti-Cancer Drugs." Biology 11, no. 8 (July 28, 2022): 1135. http://dx.doi.org/10.3390/biology11081135.

Full text
Abstract:
At present, about one-third of the total protein targets in the pharmaceutical research sector are kinase-based. While kinases have been attractive targets to combat many diseases, including cancer, selective kinase inhibition has been challenging, because of the high degree of structural homology in the active site where many kinase inhibitors bind. Despite efficacy as cancer drugs, kinase inhibitors can exhibit limited target specificity and rationalizing their target profiles in the context of precise molecular mechanisms or rearrangements is a major challenge for the field. Spectroscopic approaches such as infrared, Raman, NMR and fluorescence have the potential to provide significant insights into drug-target and drug-non-target interactions because of sensitivity to molecular environment. This review places a spotlight on the significance of fluorescence for extracting information related to structural properties, discovery of hidden conformers in solution and in target-bound state, binding properties (e.g., location of binding sites, hydrogen-bonding, hydrophobicity), kinetics as well as dynamics of kinase inhibitors. It is concluded that the information gleaned from an understanding of the intrinsic fluorescence from these classes of drugs may aid in the development of future drugs with improved side-effects and less disease resistance.
APA, Harvard, Vancouver, ISO, and other styles
3

Kondo, Shunsuke, and Nagahiro Saijo. "Target-based anti-cancer drugs." Drug Delivery System 19, no. 2 (2004): 103–9. http://dx.doi.org/10.2745/dds.19.103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lim, Young-Chai. "Pharmacogenomics of Anti-Cancer Drugs." Journal of Korean Society for Clinical Pharmacology and Therapeutics 12, no. 2 (2004): 93. http://dx.doi.org/10.12793/jkscpt.2004.12.2.93.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hofheinz, Ralf-Dieter, Senta Ulrike Gnad-Vogt, Ulrich Beyer, and Andreas Hochhaus. "Liposomal encapsulated anti-cancer drugs." Anti-Cancer Drugs 16, no. 7 (August 2005): 691–707. http://dx.doi.org/10.1097/01.cad.0000167902.53039.5a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jaouen, Gérard, Anne Vessières, and Siden Top. "Ferrocifen type anti cancer drugs." Chemical Society Reviews 44, no. 24 (2015): 8802–17. http://dx.doi.org/10.1039/c5cs00486a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Olejniczak, K. "Application to anti-cancer drugs." Toxicology Letters 205 (August 2011): S2. http://dx.doi.org/10.1016/j.toxlet.2011.05.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wu, Nan, Yizhen Xie, and Burton B. Yang. "Anti-cancer drugs for cardioprotection." Cell Cycle 16, no. 2 (November 10, 2016): 155–56. http://dx.doi.org/10.1080/15384101.2016.1242536.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fallowfield, Lesley, Valerie Jenkins, Carolyn Langridge, Ivonne Solis-Trapala, Alison Jones, and Jane Barrett. "Discussing expensive anti-cancer drugs." British Journal of Healthcare Management 17, no. 5 (May 2011): 206–12. http://dx.doi.org/10.12968/bjhc.2011.17.5.206.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tembhe, Harshada, and Rupali Tasgaonkar. "Vinca Alkaloids – Anti cancer drugs." International Journal for Research in Applied Science and Engineering Technology 11, no. 1 (January 31, 2023): 408–16. http://dx.doi.org/10.22214/ijraset.2023.48559.

Full text
Abstract:
Abstract: Cancer, one of the most common disease, is responsible for nearly 10 million deaths annually. The treatment of cancer typically includes surgery, chemotherapy, radiation therapy, and drug therapy which have a significant financial impact on patients. Also, over the time, patients may develop drug resistance. By applying evidence-based preventative techniques, a significant number of cancer cases can be avoided or treated. Plant-based medications have emerged as hopeful alternatives to chemotherapy in both developed and developing countries. Alkaloids are the secondary plant metabolites that have shown to be effective and acceptable for treating cancer. The secondmost popular family of cancer medications is vinca alkaloids, and they will continue to be utilised for cancer treatment. These medications, which include vinblastine, vincristine, vindesine, and vinorelbineare frequently used either alone or in combination with other medications. These cell cycle-dependent drugs work by preventing tubulin from polymerizing into microtubules, which causes cell death. There have been several studies looking at the pharmacological behaviour of this family of antitumor drugs in both humans and animals utilising diverse in vivo and in vitro models. Despite tremendous improvements in the prevention and control of cancer progression, there are still many flaws and space for growth. Several undesirable side effects might occasionally happen when receiving chemotherapy. Natural treatments, and hence the use of cancer therapy agents produced from plants, may reduce negative side effects.
APA, Harvard, Vancouver, ISO, and other styles
11

Blagosklonny, Mikhail V. "Selective anti-cancer agents as anti-aging drugs." Cancer Biology & Therapy 14, no. 12 (December 2013): 1092–97. http://dx.doi.org/10.4161/cbt.27350.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Ingrassia, Laurent, Isabelle Camby, Florence Lefranc, Veronique Mathieu, Prosper Nshimyumukiza, Francis Darro, and Robert Kiss. "Anti-Galectin Compounds as Potential Anti-Cancer Drugs." Current Medicinal Chemistry 13, no. 29 (December 1, 2006): 3513–27. http://dx.doi.org/10.2174/092986706779026219.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Moku, Gopikrishna, Suresh Kumar Gulla, Narendra Varma Nimmu, Sara Khalid, and Arabinda Chaudhuri. "Delivering anti-cancer drugs with endosomal pH-sensitive anti-cancer liposomes." Biomaterials Science 4, no. 4 (2016): 627–38. http://dx.doi.org/10.1039/c5bm00479a.

Full text
Abstract:
Numerous prior studies have been reported on the use of pH-sensitive drug carriers such as micelles, liposomes, peptides, polymers, nanoparticles,etc. that are sensitive to the acidic (pH = ∼6.5) microenvironments of tumor tissues.
APA, Harvard, Vancouver, ISO, and other styles
14

Lankelma, Jan. "Tissue Transport of Anti-cancer Drugs." Current Pharmaceutical Design 8, no. 22 (October 1, 2002): 1987–93. http://dx.doi.org/10.2174/1381612023393512.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Pinedo, H. M. "Development of new anti-cancer drugs." Medical Oncology and Tumor Pharmacotherapy 3, no. 2 (June 1986): 63–69. http://dx.doi.org/10.1007/bf02934555.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Vooren, K. v. d., A. Curto, and L. Garattini. "Optional copayments on anti-cancer drugs." BMJ 346, jan24 4 (January 24, 2013): f349. http://dx.doi.org/10.1136/bmj.f349.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Huettemann, Egbert, and Samir G. Sakka. "Anaesthesia and anti-cancer chemotherapeutic drugs." Current Opinion in Anaesthesiology 18, no. 3 (June 2005): 307–14. http://dx.doi.org/10.1097/01.aco.0000169240.14056.19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Wu, Xiang, Qing-hua Zhou, and Ke Xu. "Are isothiocyanates potential anti-cancer drugs?" Acta Pharmacologica Sinica 30, no. 5 (May 2009): 501–12. http://dx.doi.org/10.1038/aps.2009.50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Hirsh, Liron, Ada Dantes, Byong-Sun Suh, Yoshio Yoshida, Kumiko Hosokawa, Kimihisa Tajima, Fumikazu Kotsuji, Ofer Merimsky, and Abraham Amsterdam. "Phosphodiesterase inhibitors as anti-cancer drugs." Biochemical Pharmacology 68, no. 6 (September 2004): 981–88. http://dx.doi.org/10.1016/j.bcp.2004.05.026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

&NA;. "Anti-Cancer Drugs, Volume 1, 1990." Anti-Cancer Drugs 1, no. 2 (December 1990): 211. http://dx.doi.org/10.1097/00001813-199012000-00014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Harvey, Trevor. "Computing the best anti-cancer drugs." British Journal of Healthcare Management 7, no. 5 (May 2001): 207. http://dx.doi.org/10.12968/bjhc.2001.7.5.19112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

LEE, Siow Ming, Paul BAAS, and Heather WAKELEE. "Anti-angiogenesis drugs in lung cancer." Respirology 15, no. 3 (April 2010): 387–92. http://dx.doi.org/10.1111/j.1440-1843.2010.01715.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Rosenberg, L. "Nonsteroidal Anti-inflammatory Drugs and Cancer." Preventive Medicine 24, no. 2 (March 1995): 107–9. http://dx.doi.org/10.1006/pmed.1995.1018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Kanda, Yasunari, Takashi Yoshinaga, and Atsushi Sugiyama. "Cardiotoxicity risk of anti-cancer drugs." Proceedings for Annual Meeting of The Japanese Pharmacological Society 96 (2022): 3—B—S28–2. http://dx.doi.org/10.1254/jpssuppl.96.0_3-b-s28-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Monfardini, Silvio. "Prescribing anti-cancer drugs in elderly cancer patients." European Journal of Cancer 38, no. 18 (December 2002): 2341–46. http://dx.doi.org/10.1016/s0959-8049(02)00266-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Kwon, Yoojung, Youngmi Kim, Hyun Jung, and Dooil Jeoung. "Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance." International Journal of Molecular Sciences 20, no. 1 (December 23, 2018): 51. http://dx.doi.org/10.3390/ijms20010051.

Full text
Abstract:
Histone modification is associated with resistance to anti-cancer drugs. Epigenetic modifications of histones can regulate resistance to anti-cancer drugs. It has been reported that histone deacetylase 3 (HDAC3) regulates responses to anti-cancer drugs, angiogenic potential, and tumorigenic potential of cancer cells in association with cancer-associated genes (CAGE), and in particular, a cancer/testis antigen gene. In this paper, we report the roles of microRNAs that regulate the expression of HDAC3 and CAGE involved in resistance to anti-cancer drugs and associated mechanisms. In this review, roles of HDAC3-miRNAs-CAGE molecular networks in resistance to anti-cancer drugs, and the relevance of HDAC3 as a target for developing anti-cancer drugs are discussed.
APA, Harvard, Vancouver, ISO, and other styles
27

Neame, Bryony. "The chic delivery of anti-cancer drugs." Cancer Nursing Practice 7, no. 4 (May 2008): 18–20. http://dx.doi.org/10.7748/cnp2008.05.7.4.18.c8162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Isoldi, Mauro, Maria Visconti, and Ana Castrucci. "Anti-Cancer Drugs: Molecular Mechanisms of Action." Mini-Reviews in Medicinal Chemistry 5, no. 7 (July 1, 2005): 685–95. http://dx.doi.org/10.2174/1389557054368781.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Han, Sun-Young. "TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs." Pharmaceuticals 14, no. 7 (June 29, 2021): 632. http://dx.doi.org/10.3390/ph14070632.

Full text
Abstract:
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the presence of Trk fusion, regardless of cancer type. This unique approach, called tissue-agnostic development, expedited the process of Trk inhibitor development. In the present review, the development processes of larotrectinib and entrectinib have been described, along with discussion on other Trk inhibitors currently in clinical trials. The on-target effects of Trk inhibitors in Trk signaling exhibit adverse effects on the central nervous system, such as withdrawal pain, weight gain, and dizziness. A next generation sequencing-based method has been approved for companion diagnostics of larotrectinib, which can detect various types of Trk fusions in tumor samples. With the adoption of the tissue-agnostic approach, the development of Trk inhibitors has been accelerated.
APA, Harvard, Vancouver, ISO, and other styles
30

Strohfeldt, Katja, and Matthias Tacke. "Bioorganometallic fulvene-derived titanocene anti-cancer drugs." Chemical Society Reviews 37, no. 6 (2008): 1174. http://dx.doi.org/10.1039/b707310k.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Baron, John A., and Robert S. Sandler. "Nonsteroidal Anti-Inflammatory Drugs and Cancer Prevention." Annual Review of Medicine 51, no. 1 (February 2000): 511–23. http://dx.doi.org/10.1146/annurev.med.51.1.511.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

TOPTANCI, Bircan Çeken, Göksel KIZIL, and Murat KIZIL. "DNA DAMAGE MECHANISMS OF ANTI-CANCER DRUGS." Middle East Journal of Science 2, no. 1 (June 26, 2016): 33–49. http://dx.doi.org/10.23884/mejs/2016.2.1.03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

TOPTANCI, Bircan Çeken, Göksel KIZIL, and Murat KIZIL. "DNA DAMAGE MECHANISMS OF ANTI-CANCER DRUGS." Middle East Journal of Science 2, no. 1 (June 29, 2016): 33–49. http://dx.doi.org/10.23884/mejs/2017.2.03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Strawson, Jenny. "Nonsteroidal anti-inflammatory drugs and cancer pain." Current Opinion in Supportive and Palliative Care 12, no. 2 (June 2018): 102–7. http://dx.doi.org/10.1097/spc.0000000000000332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Sweeney, Nigel J., Oscar Mendoza, Helge Müller-Bunz, Clara Pampillón, Franz-Josef K. Rehmann, Katja Strohfeldt, and Matthias Tacke. "Novel benzyl substituted titanocene anti-cancer drugs." Journal of Organometallic Chemistry 690, no. 21-22 (November 2005): 4537–44. http://dx.doi.org/10.1016/j.jorganchem.2005.06.039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Barrett, S. V., and M. P. Barrett. "Anti-sleeping Sickness Drugs and Cancer Chemotherapy." Parasitology Today 16, no. 1 (January 2000): 7–9. http://dx.doi.org/10.1016/s0169-4758(99)01560-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Pampillón, Clara, Oscar Mendoza, Nigel J. Sweeney, Katja Strohfeldt, and Matthias Tacke. "Diarylmethyl substituted titanocenes: Promising anti-cancer drugs." Polyhedron 25, no. 10 (July 2006): 2101–8. http://dx.doi.org/10.1016/j.poly.2006.01.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

NAPOLI, DENISE. "Anti-TNF Drugs Tied to Skin Cancer." Internal Medicine News 42, no. 20 (November 2009): 43. http://dx.doi.org/10.1016/s1097-8690(09)70833-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

LIN, CHUN-NAN, SHIOU-JYH LIOU, TAI-HUA LEE, YIN-CHING CHUANG, and SHEN-JEU WON. "Xanthone Derivatives as Potential Anti-cancer Drugs." Journal of Pharmacy and Pharmacology 48, no. 5 (May 1996): 539–44. http://dx.doi.org/10.1111/j.2042-7158.1996.tb05970.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

van de Vooren, Katelijne, Alessandro Curto, Nick Freemantle, and Livio Garattini. "Market-access agreements for anti-cancer drugs." Journal of the Royal Society of Medicine 108, no. 5 (December 8, 2014): 166–70. http://dx.doi.org/10.1177/0141076814559626.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Ndinguri, Margaret W., Rajasree Solipuram, Robert P. Gambrell, Sita Aggarwal, and Robert P. Hammer. "Peptide Targeting of Platinum Anti-Cancer Drugs." Bioconjugate Chemistry 20, no. 10 (October 21, 2009): 1869–78. http://dx.doi.org/10.1021/bc900065r.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Dredge, Keith, Angus G. Dalgleish, and J. Blake Marriott. "Thalidomide analogs as emerging anti-cancer drugs." Anti-Cancer Drugs 14, no. 5 (June 2003): 331–35. http://dx.doi.org/10.1097/00001813-200306000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Haseeb, Muhammad, and Shahid Hussain. "Pharmacophore Development for Anti-Lung Cancer Drugs." Asian Pacific Journal of Cancer Prevention 16, no. 18 (January 11, 2016): 8307–11. http://dx.doi.org/10.7314/apjcp.2015.16.18.8307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Huang, Jing, Danwei Zhao, Zhixiong Liu, and Fangkun Liu. "Repurposing psychiatric drugs as anti-cancer agents." Cancer Letters 419 (April 2018): 257–65. http://dx.doi.org/10.1016/j.canlet.2018.01.058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

&NA;. "Against early registration of anti-cancer and anti-HIV drugs." Inpharma Weekly &NA;, no. 988 (May 1995): 6. http://dx.doi.org/10.2165/00128413-199509880-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Quezada, Héctor, Mariano Martínez-Vázquez, Esaú López-Jácome, Bertha González-Pedrajo, Ángel Andrade, Ana María Fernández-Presas, Arturo Tovar-García, and Rodolfo García-Contreras. "Repurposed anti-cancer drugs: the future for anti-infective therapy?" Expert Review of Anti-infective Therapy 18, no. 7 (April 15, 2020): 609–12. http://dx.doi.org/10.1080/14787210.2020.1752665.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Song, Bomi, Eun Young Park, Kwang Joon Kim, and Sung Hwan Ki. "Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics." Cancers 14, no. 19 (September 22, 2022): 4601. http://dx.doi.org/10.3390/cancers14194601.

Full text
Abstract:
Benzimidazoles have shown significant promise for repurposing as a cancer therapy. The aims of this review are to investigate the possibilities and limitations of the anti-cancer effects of benzimidazole anthelmintics and to suggest ways to overcome these limitations. This review included studies on the anti-cancer effects of 11 benzimidazoles. Largely divided into three parts, i.e., preclinical anti-cancer effects, clinical anti-cancer effects, and pharmacokinetic properties, we examine the characteristics of each benzimidazole and attempt to elucidate its key properties. Although many studies have demonstrated the anti-cancer effects of benzimidazoles, there is limited evidence regarding their effects in clinical settings. This might be because the clinical trials conducted using benzimidazoles failed to restrict their participants with specific criteria including cancer entities, cancer stages, and genetic characteristics of the participants. In addition, these drugs have limitations including low bioavailability, which results in insufficient plasma concentration levels. Additional studies on whole anti-cancer pathways and development strategies, including formulations, could result significant enhancements of the anti-cancer effects of benzimidazoles in clinical situations.
APA, Harvard, Vancouver, ISO, and other styles
48

Zappavigna, Silvia, Alessia Maria Cossu, Anna Grimaldi, Marco Bocchetti, Giuseppe Andrea Ferraro, Giovanni Francesco Nicoletti, Rosanna Filosa, and Michele Caraglia. "Anti-Inflammatory Drugs as Anticancer Agents." International Journal of Molecular Sciences 21, no. 7 (April 9, 2020): 2605. http://dx.doi.org/10.3390/ijms21072605.

Full text
Abstract:
Inflammation is strictly associated with cancer and plays a key role in tumor development and progression. Several epidemiological studies have demonstrated that inflammation can predispose to tumors, therefore targeting inflammation and the molecules involved in the inflammatory process could represent a good strategy for cancer prevention and therapy. In the past, several clinical studies have demonstrated that many anti-inflammatory agents, including non-steroidal anti-inflammatory drugs (NSAIDs), are able to interfere with the tumor microenvironment by reducing cell migration and increasing apoptosis and chemo-sensitivity. This review focuses on the link between inflammation and cancer by describing the anti-inflammatory agents used in cancer therapy, and their mechanisms of action, emphasizing the use of novel anti-inflammatory agents with significant anticancer activity.
APA, Harvard, Vancouver, ISO, and other styles
49

Ostroumova, O. D., D. A. Sychev, A. I. Kochetkov, T. M. Ostroumova, M. I. Kulikova, and V. A. De. "Anti-cancer agents and drug-induced hypertension." Medical alphabet, no. 17 (September 7, 2022): 30–41. http://dx.doi.org/10.33667/2078-5631-2022-17-30-41.

Full text
Abstract:
Arterial hypertension is one of the most common comorbidities in patients with cancer. Moreover, the treatment with anticancer agents can lead to the development of drug-induced arterial hypertension. The aim of this work is to systematize and analyze data about anticancer agents, the use of which can cause the development of drug-induced hypertension, about epidemiology, pathophysiological mechanisms, risk factors, clinical signs, diagnosis and differential diagnosis, treatment and prevention of hypertension associated with the use of anticancer drugs. It was found that anti-cancer drugs often contribute to the development of drug-induced hypertension. The mechanisms that determine the development of hypertension are diverse and may include the development of endothelial dysfunction, an increased arterial stiffness, capillary rarefaction, fluid and electrolyte imbalance, and genetic factors. It is important to remember about drugs that can cause drug-induced hypertension to reduce the risk of developing adverse reactions, and prevent cardiovascular disease. Treatment of drug-induced hypertension, caused by anticancer drugs, often requires immediate discontinuation of drugs, due to adverse reactions that are often life-threatening. In some situations, it is possible to reduce the dose of the drugs and / or prescribe antihypertensive drugs. Arterial hypertension is an important risk factor in the development of cardiovascular events, including stroke, coronary heart disease, heart failure.
APA, Harvard, Vancouver, ISO, and other styles
50

Fond, G., A. Macgregor, J. Attal, A. Larue, M. Brittner, D. Ducasse, and D. Capdevielle. "Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review." Medical Hypotheses 79, no. 1 (July 2012): 38–42. http://dx.doi.org/10.1016/j.mehy.2012.03.026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Anti-cancer drugs' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography